Merlin/NF2 regulates angiogenesis in schwannomas through a Rac1/semaphorin 3F-dependent mechanism

Neoplasia

Volumn 14, Issue 2, 2012, Pages 84-94

  Wong, Hon Kit ^a,c   Shimizu, Akio ^b   Kirkpatrick, Nathaniel D ^a   Garkavtsev, Igor ^a   Chan, Annie W ^a   di Tomaso, Emmanuelle ^a,d   Klagsbrun, Michael ^b   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERLIN; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SEMAPHORIN 3F; THROMBOSPONDIN 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; DNA MICROARRAY; DOWN REGULATION; DRUG TARGETING; GENE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NEURILEMOMA; NEUROFIBROMATOSIS; NF2 GENE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SURVIVAL RATE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; VASCULAR TUMOR; WESTERN BLOTTING;

EID: 84858053975     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111600     Document Type: Article

References (44)

1. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, and Lonser RR (2009). Neurofibromatosis type 2. Lancet 373, 1974-1986.
2. Mrugala MM, Batchelor TT, and Plotkin SR (2005). Peripheral and cranial nerve sheath tumors. Curr Opin Neurol 18, 604-610.
3. Plotkin SR, Stemmer-Rachamimov AO, Barker FG II, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, and di Tomaso E (2009). Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361, 358-367.
4. Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, and di Tomaso E (2010). Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 70, 3483-3493.
5. Caye-Thomasen P, Baandrup L, Jacobsen GK, Thomsen J, and Stangerup SE (2003). Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 113, 2129-2134.
6. Caye-Thomasen P, Werther K, Nalla A, Bog-Hansen TC, Nielsen HJ, Stangerup SE, and Thomsen J (2005). VEGF and VEGF receptor-1 concentration in ves-tibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 26, 98-101.
7. Koutsimpelas D, Stripf T, Heinrich UR, Mann WJ, and Brieger J (2007). Expression of vascular endothelial growth factor and basic fibroblast growthfactor in sporadic vestibular schwannomas correlates to growth characteristics. Otol Neurotol 28, 1094-1099.
8. Uesaka T, Shono T, Suzuki SO, Nakamizo A, Niiro H, Mizoguchi M, Iwaki T, and Sasaki T (2007). Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol 83, 259-266.
9. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62.
10. Yazdani U and Terman JR (2006). The semaphorins. Genome Biol 7, 211.
11. Chen H, He Z, and Tessier-Lavigne M (1998). Axon guidance mechanisms: semaphorins as simultaneous repellents and anti-repellents. Nat Neurosci 1, 436-439.
12. Luo Y, Raible D, and Raper JA (1993). Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 75, 217-227.
13. Puschel AW, Adams RH, and Betz H (1995). Murine semaphorin D/collapsin is a member of a diverse gene family and creates domains inhibitory for axonal extension. Neuron 14, 941-948.
14. Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, and Klagsbrun M (1999). Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146, 233-242.
15. Kessler O, Shraga-Heled N, Lange T, Gutmann-Raviv N, Sabo E, Baruch L, Machluf M, and Neufeld G (2004). Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64, 1008-1015.
16. Neufeld G, Lange T, Varshavsky A, and Kessler O (2007). Semaphorin signaling in vascular and tumor biology. Adv Exp Med Biol 600, 118-131.
17. Bielenberg DR and Klagsbrun M (2007). Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev 26, 421-431.
18. Takahashi T and Strittmatter SM (2001). Plexina1 autoinhibition by the plexin sema domain. Neuron 29, 429-439.
19. Bielenberg DR, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim CC, and Klagsbrun M (2004). Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 114, 1260-1271.
20. Coma S, Amin DN, Shimizu A, Lasorella A, Iavarone A, and Klagsbrun M (2010). Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F. Cancer Res 70, 3823-3832.
21. Shimizu A, Mammoto A, Italiano JE Jr, Pravda E, Dudley AC, Ingber DE, and Klagsbrun M (2008). ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells. J Biol Chem 283, 27230-27238.
22. Ketteler R, Glaser S, Sandra O, Martens UM, and Klingmuller U (2002). Enhanced transgene expression in primitive hematopoietic progenitor cells and embryonic stem cells efficiently transduced by optimized retroviral hybrid vectors. Gene Ther 9, 477-487.
23. Gualdoni S, Albertinazzi C, Corbetta S, Valtorta F, and de Curtis I (2007). Normal levels of Rac1 are important for dendritic but not axonal development in hippocampal neurons. Biol Cell 99, 455-464.
24. Hung G, Li X, Faudoa R, Xeu Z, Kluwe L, Rhim JS, Slattery W, and Lim D (2002). Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int J Oncol 20, 475-482.
25. Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, and Breakefield XO (2007). Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Δ. Cancer Gene Ther 14, 460-467.
26. Kaempchen K, Mielke K, Utermark T, Langmesser S, and Hanemann CO (2003). Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells. Hum Mol Genet 12, 1211-1221.
27. Flaiz C, Kaempchen K, Matthies C, and Hanemann CO (2007). Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannomas. J Neuropathol Exp Neurol 66, 608-616.
28. Lopes N, Gregg D, Vasudevan S, Hassanain H, Goldschmidt-Clermont P, and Kovacic H (2003). Thrombospondin 2 regulates cell proliferation induced by Rac1 redox-dependent signaling. Mol Cell Biol 23, 5401-5408.
29. Morrison H, Sperka T, Manent J, Giovannini M, Ponta H, and Herrlich P (2007). Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 67, 520-527.
30. Jin Z and Strittmatter SM (1997). Rac1 mediates collapsin-1-induced growth cone collapse. J Neurosci 17, 6256-6263.
31. Kuhn TB, Brown MD, Wilcox CL, Raper JA, and Bamburg JR (1999). Myelin and collapsin-1 induce motor neuron growth cone collapse through different pathways: inhibition of collapse by opposing mutants of rac1. J Neurosci 19, 1965-1975.
32. Vastrik I, Eickholt BJ, Walsh FS, Ridley A, and Doherty P (1999). Sema3A-induced growth-cone collapse is mediated by Rac1 amino acids 17-32. Curr Biol 9, 991-998.
33. Kim YB, Yu J, Lee SY, Lee MS, Ko SG, Ye SK, Jong HS, Kim TY, Bang YJ, and Lee JW (2005). Cell adhesion status-dependent histone acetylation is regulated through intracellular contractility-related signaling activities. J Biol Chem 280, 28357-28364.
34. Gao YS, Hubbert CC, Lu J, Lee YS, Lee JY, and Yao TP (2007). Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol 27, 8637-8647.
35. Kusy S, Potiron V, Zeng C, Franklin W, Brambilla E, Minna J, Drabkin HA, and Roche J (2005). Promoter characterization of semaphorin SEMA3F, a tumor suppressor gene. Biochim Biophys Acta 1730, 66-76.
36. Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M, Seano G, Serini G, Bussolino F, and Giraudo E (2009). Semaphorin 3A is an endogenous angio-genesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest 119, 3356-3372.
37. Bornstein P (2009). Thrombospondins function as regulators of angiogenesis. J Cell Commun Signal 3, 189-200.
38. Chandrasekaran L, He CZ, Al-Barazi H, Krutzsch HC, Iruela-Arispe ML, and Roberts DD (2000). Cell contact-dependent activation of α3β1 integrin modulates endothelial cell responses to thrombospondin-1. Mol Biol Cell 11, 2885-2900.
39. Qian X, Wang TN, Rothman VL, Nicosia RF, and Tuszynski GP (1997). Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. Exp Cell Res 235, 403-412.
40. Staniszewska I, Zaveri S, Del Valle L, Oliva I, Rothman VL, Croul SE, Roberts DD, Mosher DF, Tuszynski GP, and Marcinkiewicz C (2007). Interaction of α9β1 integrin with thrombospondin-1 promotes angiogenesis. Circ Res 100, 1308-1316.
41. Taraboletti G, Morbidelli L, Donnini S, Parenti A, Granger HJ, Giavazzi R, and Ziche M (2000). The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J 14, 1674-1676.
42. Bornstein P, Armstrong LC, Hankenson KD, Kyriakides TR, and Yang Z (2000). Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol 19, 557-568.
43. Watnick RS, Cheng YN, Rangarajan A, Ince TA, and Weinberg RA (2003). Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 3, 219-231.
44. Bein K, Ware JA, and Simons M (1998). Myb-dependent regulation of thrombospondin 2 expression. Role of mRNA stability. J Biol Chem 273, 21423-21429.